• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ADVANCE trial: Intensive glycemic control reduces risk of nephropathy [Classics Series]

byAndrew Cheung, MD MBA
October 3, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Intensive glycemic control was associated with significantly lower rates of new or worsened nephropathy when compared to conventional glycemic control.

2. There was no significant reduction in major macrovascular events associated with intensive blood sugar control.

Original Date of Publication: June 12, 2008

Study Rundown: Glycated haemoglobin (HbA1c) levels are frequently used as a marker of glycemic control in diabetic patients. Previous studies, such as the ACCORD and UKPDS trials, have demonstrated that tighter glycemic control reduces the risk of microvascular complications (i.e., nephropathy, retinopathy, neuropathy). The ACCORD trial, however, also noted that there was significantly higher risk of mortality in patients who underwent tight glycemic control (i.e., target HbA1c <6.0%). Moreover, there is no strong evidence demonstrating that better glycemic control significantly improves rates of macrovascular complications (i.e., myocardial infarction, stroke).

The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial sought to assess the effects of intensive glycemic control (i.e., target HbA1c ≤6.5%) on vascular outcomes. The findings demonstrate that patients in the intensive group had significantly lower risk of new/worsening nephropathy (HR 0.79; 95%CI 0.66-0.93) and new-onset microalbuminuria (HR 0.91; 95%CI 0.85-0.98) when compared with standard therapy. There were no significant differences between the two groups in rates of macrovascular complications or all-cause mortality. Importantly, the risk of severe hypoglycaemia was significantly higher in patients undergoing intensive therapy (HR 1.86; 95%CI 1.42-2.40).

Click to read the study in NEJM

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

In-Depth [randomized controlled study]: The study included 11,140 participants from 215 centres in 20 countries. Patients were eligible if they were ≥55 years of age, were diagnosed with type 2 diabetes mellitus at ≥30 years of age, and had a history of micro- or macrovascular disease. Exclusion criteria included a definite indication for or contraindication to any of the study drugs, or a definite indication for long-term insulin therapy at study entry. Included patients were randomized to either intensive glucose control (i.e., target HbA1c ≤6.5%) or standard glucose control (i.e., based on local guidelines). The intensive control group received gliclazide and other adjuvants to achieve target HbA1c, while the control group received treatment as per local guidelines. The primary outcome was a composite of macrovascular (i.e., myocardial infarction, stroke, or death from cardiovascular event) and microvascular events (nephropathy or retinopathy).

Median follow-up time was 5 years. At the end of the follow-up period, the mean HbA1c levels were 6.5% and 7.3% in the intensive and standard groups, respectively. There were no significant differences between the two groups with regards to the incidence of major macrovascular events (HR 0.94; 95%CI 0.84-1.06) and death from any cause (HR 0.93; 95%CI 0.83-1.06). The intensive group had a significantly lower rate of major microvascular events (HR 0.86; 95%CI 0.77-0.97), which was driven by a significantly lower risk of new or worsening nephropathy (HR 0.79; 95%CI 0.66-0.93) and new-onset microalbuminuria (HR 0.91; 95%CI 0.85-0.98). There was no significant difference between the two groups in terms of the risk of new or worsening retinopathy. The risk of severe hypoglycaemia, however, was significantly higher in the intensive group (HR 1.86; 95%CI 1.42-2.40).

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: advance trialdiabetestype 2 diabetes
Previous Post

Long-term physical activity is associated with several health markers in the serum metabolome

Next Post

[Physician Comment] Suture closure superior to staples after cesarean delivery

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post
[Physician Comment] Suture closure superior to staples after cesarean delivery

[Physician Comment] Suture closure superior to staples after cesarean delivery

[Researcher Comment] The virtual lumbar puncture: MRI can predict CSF biomarker levels in patients with neurodegenerative disease

[Physician Comment] Pneumocystis linked to Sudden Unexpected Infant Deaths

[Physician Comment] Pneumocystis linked to Sudden Unexpected Infant Deaths

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.